Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 7, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.02156-21
Keywords
invasive aspergillosis; voriconazole; isavuconazole; therapeutic drug monitoring; immunocompromised children; posaconazole
Categories
Funding
- Pfizer
- Merck
Ask authors/readers for more resources
This review discusses the role of voriconazole and other drugs in the treatment of invasive aspergillosis in children, as well as the importance of therapeutic drug monitoring.
Invasive aspergillosis (IA) is associated with significant morbidity and mortality. Voriconazole remains the drug of choice for the treatment of IA in children; however, the complex kinetics of voriconazole in children make dosing challenging and therapeutic drug monitoring (TDM) essential for treatment success. The overarching goal of this review is to discuss the role of voriconazole, posaconazole, isavuconazole, liposomal amphotericin B, echinocandins, and combination antifungal therapy for the treatment of IA in children. We also provide a detailed discussion of antifungal TDM in children.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available